SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank30
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Latest
-24.38%
↑ 43% vs avg
Percentile
P30
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
-42.65%
Historical baseline
PeriodValue
Q4 2025-24.38%
Q3 2025-30.28%
Q2 20259.65%
Q1 2025-7.63%
Q4 202411.50%
Q3 2024-10.86%
Q2 202410.44%
Q1 202439.65%
Q4 2023-254.57%
Q3 202317.81%
Q2 202312.50%
Q1 20235.83%
Q4 2022-0.67%
Q3 2022-19.32%
Q2 20222.45%
Q1 20228.67%
Q4 2021-84.05%
Q3 2021-38.91%
Q2 2021-452.92%
Q1 2021-90.52%
Q4 20200.00%